Stockholm, Sweden, August 19, 2022; Inify Laboratories AB ("Inify") has been
notified that the following transaction has been completed by a close associate
to a primary insider in Inify: Monsun AS, a Norwegian company controlled by
Magne Jordanger, board member and primary insider in Inify, has bought 336,950
shares in Inify at an average price of NOK 7.6 per share. After the transaction,
Monsun AS holds 336,950 shares. Please refer to the attached notification of
trading for further details.

This information is subject to the disclosure requirements in the EU Market
Abuse Regulation (EU 596/2014 article 19) and section 5-12 of the Norwegian
Securities Trading Act.

For more information, please contact CEO Fredrik Palm (fredrik.palm@inify.com)
or visit www.inify.com

About Inify Laboratories AB (publ)

Inify Laboratories provides cancer diagnostics through ultra-modern laboratory
services within histopathology. Fully digital, standardized and AI- supported
workflow is applied to optimize quality and response times, initially for
prostate cancer. The concept is scalable and extendible to other diagnosis. The
company origins from ContextVision and became independent in February 2022. The
company is based in Sweden and listed on Euronext Growth Oslo under the ticker
INIFY